AstraZeneca partner Peregrine scraps its R&D game plan in wake of PhIII flop

AstraZeneca partner Peregrine scraps its R&D game plan in wake of PhIII flop

AstraZeneca London HQ Faced with a Phase III failure for its lead cancer drug, Peregrine Pharmaceuticals is drawing up a new R&D game plan. The company says it is scrapping Phase II and Phase III efforts for bavituximab, retreating to a series of small, early-stage combination studies with immunotherapy drugs. Bavituximab was ruled a flop back on February when Peregrine announced that a combo […]

Facebooktwittergoogle_plusredditpinterestlinkedinmail
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *